Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Down 10.9%

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)’s stock price was down 10.9% during mid-day trading on Thursday . The stock traded as low as $13.18 and last traded at $13.54. Approximately 1,255,054 shares changed hands during trading, an increase of 62% from the average daily volume of 776,140 shares. The stock had previously closed at $15.19.

Analyst Ratings Changes

DAWN has been the subject of a number of recent research reports. Wedbush reaffirmed an “outperform” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research note on Wednesday. Oppenheimer reissued a “market perform” rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. Needham & Company LLC raised their target price on Day One Biopharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a report on Wednesday. Piper Sandler reiterated an “overweight” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. Finally, The Goldman Sachs Group lowered their price objective on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a research note on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $39.33.

Day One Biopharmaceuticals Stock Down 13.0 %

The business has a 50-day moving average price of $15.28 and a 200-day moving average price of $13.79. The firm has a market capitalization of $1.15 billion, a P/E ratio of -5.68 and a beta of -1.48.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings results on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). As a group, sell-side analysts forecast that Day One Biopharmaceuticals, Inc. will post -2.66 EPS for the current year.

Insider Activity at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 10,000 shares of the firm’s stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $16.02, for a total transaction of $160,200.00. Following the completion of the transaction, the insider now owns 1,174,662 shares in the company, valued at $18,818,085.24. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, insider Samuel C. Blackman sold 2,258 shares of the business’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $34,434.50. Following the sale, the insider now owns 1,244,662 shares of the company’s stock, valued at approximately $18,981,095.50. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Samuel C. Blackman sold 10,000 shares of the stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $16.02, for a total value of $160,200.00. Following the transaction, the insider now owns 1,174,662 shares of the company’s stock, valued at $18,818,085.24. The disclosure for this sale can be found here. Insiders have sold a total of 55,781 shares of company stock valued at $883,160 over the last quarter. 8.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Hennion & Walsh Asset Management Inc. increased its position in shares of Day One Biopharmaceuticals by 2.5% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 59,289 shares of the company’s stock worth $979,000 after purchasing an additional 1,445 shares in the last quarter. Fisher Asset Management LLC increased its holdings in shares of Day One Biopharmaceuticals by 89.0% during the fourth quarter. Fisher Asset Management LLC now owns 68,446 shares of the company’s stock worth $999,000 after buying an additional 32,238 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Day One Biopharmaceuticals by 77.7% in the fourth quarter. Wellington Management Group LLP now owns 208,969 shares of the company’s stock valued at $3,051,000 after acquiring an additional 91,393 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Day One Biopharmaceuticals by 28.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock valued at $30,935,000 after acquiring an additional 472,654 shares during the last quarter. Finally, Quintet Private Bank Europe S.A. boosted its holdings in shares of Day One Biopharmaceuticals by 43.2% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after acquiring an additional 1,000 shares in the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.